Cargando…
Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
BACKGROUND: The development of immunotherapy has led to significant progress in the treatment of metastatic cancer, including the development of genetic engineering technologies that redirect lymphocytes to recognize and target a wide variety of tumor antigens. Chimeric antigen receptors (CARs) are...
Autores principales: | Beard, Rachel E, Zheng, Zhili, Lagisetty, Kiran H, Burns, William R, Tran, Eric, Hewitt, Stephen M, Abate-Daga, Daniel, Rosati, Shannon F, Fine, Howard A, Ferrone, Soldano, Rosenberg, Steven A, Morgan, Richard A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155770/ https://www.ncbi.nlm.nih.gov/pubmed/25197555 http://dx.doi.org/10.1186/2051-1426-2-25 |
Ejemplares similares
-
Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms
por: Yang, Jianbo, et al.
Publicado: (2004) -
Chondroitin Sulfate Proteoglycan-4 (CSPG4)-Specific Monoclonal Antibody 225.28 in Detection of Acute Myeloid Leukemia Blasts
por: Fenton, Moon, et al.
Publicado: (2015) -
Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy
por: Nota, Sjoerd P. F. T., et al.
Publicado: (2022) -
(212)Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models
por: Kasten, Benjamin B., et al.
Publicado: (2018) -
Chondroitin sulfate proteoglycan 4 specific chimeric antigen receptor therapy for pediatric solid tumors
por: Tschernia, Nicholas, et al.
Publicado: (2014)